Daratumumab (Anti-CD38) interference with serological testing: An emerging challenge for blood banks in developing countries

Daratumumab (Anti-CD38) interference with serological testing: An emerging challenge for blood banks in developing countries

Daratumumab (DARA), a monoclonal anti-CD38 antibody, belongs to the new generation of immunotherapy in refractory relapsed multiple myeloma. CD38 is weakly expressed on human erythrocytes. By its intrinsic anti-CD38 activity, DARA also interferes in routine pretransfusion compatibility testing such...

Full description

Bibliographic Details
Main Authors: Rasika Setia, Mitu Dogra, Prerna Sachdeva, Anil Handoo, Dharma Choudhary, Amit Agarwal
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-01-01
Series:Global Journal of Transfusion Medicine
Subjects:
Anti-CD38
antibody screening
compatibility testing
daratumumab
dithiothreitol
red blood cells
serological interference
Online Access:http://www.gjtmonline.com/article.asp?issn=2468-8398;year=2017;volume=2;issue=2;spage=163;epage=165;aulast=Setia

Internet

http://www.gjtmonline.com/article.asp?issn=2468-8398;year=2017;volume=2;issue=2;spage=163;epage=165;aulast=Setia

Similar Items